Morgan Bron, PharmD

HEOR Lead
Neurocrine Biosciences, Inc.

Poster(s):

• (59) Indirect treatment comparison for early efficacy of VMAT2 inhibitors for tardive dyskinesia and chorea associated with Huntington’s disease
  Wednesday, October 29, 2025

• (60) Valbenazine improves the impacts and symptoms of tardive dyskinesia: results from the phase 4 kinect-pro study
  Wednesday, October 29, 2025

• (347) Estimation of the minimal clinically important difference (MCID) and longitudinal change in the tardive dyskinesia impact scale (TDIS), a validated, tardive dyskinesia-specific, patient-reported outcome measure
  Wednesday, October 29, 2025

• (363) Real-world insights on tardive dyskinesia: a claims-based analysis of demographics and healthcare utilization
  Wednesday, October 29, 2025